News and Events
Study finds that enzyme can disentangle strands of DNA and RNA
R-loops are three-stranded hybrid structures of DNA and RNA that play important regulatory functions in cells. Tangled R-loops can cause a number of issues in the genome and subsequently affect people’s health. CCR researchers have uncovered the mechanisms that the enzyme topoisomerase 3B uses to disentangle problematic R-loops.
Read More
Registration now open for the Metastatic Niche Symposium!
This symposium brings together world-leading researchers in the field of metastasis, stem cells, tumor microenvironment and cancer progression in the vibrant setting of Bethesda, MD, steps from the nation’s capital. Register here.
Read More
A phase II study tests a new drug for patients with advanced thyroid cancer
A phase II trial of CUDC-907, a new drug that may be able to shrink thyroid tumors that have spread or gotten worse, is being tested in metastatic or advanced thyroid cancer. Currently, there is no standard or effective treatment for the most aggressive types of thyroid cancer such as anaplastic and poorly differentiated thyroid cancer. Learn more...
Read More
William Dahut leads discussion of prostate cancer treatment options
William Dahut, M.D., CCR Scientific Director for Clinical Research, was joined by Heather Cheng, M.D., of the University of Washington for a discussion about current and future research areas and treatment options for prostate cancer. The panel was moderated by Ana Fadich, Vice President of the Men's Health Network. Learn more...
Read More
Dr. Alex Compton appointed as tenure track investigator
Alex Compton, Ph.D. has joined the HIV Dynamics and Replication Program (HIV DRP) as a tenure track Investigator. Dr. Compton’s research is broadly focused on the antiviral innate immune response against HIV-1 infection. Learn more...
Read More
Christian Hinrichs discusses cancer research with PBS NewsHour’s Hari Sreenivasan
PBS NewsHour’s Hari Sreenivasan interviewed Christian Hinrichs, M.D., on Facebook Live to discuss cancer research and immunotherapy in Hinrichs’ lab. Hinrichs is an investigator who works in the Experimental Transplantation and Immunology Branch and researches immunotherapy for HPV cancers. He says: “We’re very much on a mission here. It’s not a casual exploration. We’re trying to get better treatments and get them to the patients as quickly as possible. I think this is true of everybody in our lab. We get up and that’s what we’re trying to do is find a better treatment and get it to the patients. We’re trying to get more patients treated, and then the patients we’ve treated we’re trying to understand what’s going on with those patients so we can make better therapies.”
Read More
Novel target for high-risk neuroblastoma identified in pre-clinical research
Pre-clinical research by investigators at the Center for Cancer Research and their colleagues have identified a number of novel epigenetic targets for high-risk neuroblastoma and validated a promising new targeted inhibitor in pre-clinical models. Read more...
Read More